Denosumab: the next first-line drug for bone metastases?
23 September 2009
Asher Mullard
Amgen's denosumab has the potential to become a first-line therapy for bone metastases, according to lead investigators of two Phase III trials of the drug. Detailed data of the trials, presented at the ECCO-ESMO conference in Berlin this week, suggest that the drug has equivalent and sometimes superior...
Please Login to read the full article.
23 September 2009
Asher Mullard
Please Login to read the full article.
RELATED CONTENT
NEWS
- With questions raised on prostate cancer benefit, Amgen's Xgeva may face tough ODAC
- Japanese denosumab approval furthers Daiichi Sankyo's oncology ambitions
- AstraZeneca boosts oncology portfolio in Japan with Daiichi denosumab deal
- Amgen & UCB unveil positive AMG 785/CDP7851 PMO data
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
